Also trades as: COPN.SW (SIX) · $vol 3M
CMOPF OTC
Cosmo Pharmaceuticals N.V.
1W: -9.8%
1M: -8.6%
3M: -24.6%
YTD: -54.6%
1Y: -22.4%
3Y: +60.0%
5Y: -20.8%
$63.10
-2.40 (-3.66%)
Weekly Expected Move ±7.0%
$54
$59
$63
$68
$72
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$12M
-107.2% ▼
Capital Expenditures
$4M
+25.2% ▲
5Y CAGR: -12.1%
Free Cash Flow
-$16M
-110.1% ▼
Dividends Paid
$33M
-2.5% ▼
Buybacks
$8M
-34.3% ▼
Net Change in Cash
$17M
+381.8% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $24M | $24M | $2M | $153M | -$4M |
| Depreciation & Amort. | $7M | $14M | $14M | $12M | $13M |
| Stock-Based Comp. | $1M | $2M | $4M | $2M | $0 |
| Change in Working Capital | -$5M | -$13M | $946K | $113K | -$4M |
| Other Non-Cash Items | $6M | $6M | $2M | -$5M | -$16M |
| Operating Cash Flow | $13M | $33M | $23M | $162M | -$12M |
| — Investing Activities — | |||||
| Capital Expenditures | -$9M | -$7M | -$3M | -$5M | -$5M |
| Acquisitions (Net) | $23M | $0 | $0 | $0 | $0 |
| Investment Purchases | -$1M | -$54M | -$61M | -$157M | -$30M |
| Investment Sales | $8M | $36M | $118M | $34M | $86M |
| Other Investing | $3M | $27M | -$11M | -$875K | $0 |
| Investing Cash Flow | $25M | $2M | $42M | -$129M | $50M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$3M | -$916K | -$176M | -$1M | -$1M |
| Stock Repurchased | -$21M | -$25M | -$12M | -$6M | -$8M |
| Dividends Paid | $0 | -$16M | -$17M | -$32M | -$33M |
| Other Financing | -$5M | -$5M | -$6M | -$4M | -$5M |
| Financing Cash Flow | -$27M | -$46M | -$211M | -$40M | -$25M |
| Net Change in Cash | $13M | -$13M | -$136M | -$6M | $17M |
| Cash End of Period | $199M | $186M | $50M | $44M | $56M |
| Free Cash Flow | $4M | $26M | $18M | $157M | -$16M |